Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Liraglutide
Victoza
Not routinely available
SMC (585/09)
02/02/2022
Indication
Type 2 Diabetes. SMC Restriction: Liraglutide is restricted to use as a third-line antidiabetic agent.
Therapeutic Area
Endocrine system
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
6mg/mL prefilled pen for injection